HOME >> BIOLOGY >> NEWS
AVAX Technologies' M-Vax™ cancer vaccine induces T cell mediated immune reactions in patients with metastatic melanoma

AVAX Technologies, Inc. (NASDAQ: AVXT) today announced the presentation of data at the 91st Annual Meeting of the American Association for Cancer Research (AACR), which indicate that M-Vax™, a cancer vaccine made from the patient's own tumor cells, induces T cell infiltration of metastatic sites. T cells are the class of white blood cells believed to be instrumental in fighting cancer cells. The presentation, entitled "T cell receptor structure of lymphocytes infiltrating melanoma metastases after administration of autologous, dinitrophenyl-modified vaccine," showed data that continue to validate earlier results demonstrating that M-Vax elicits an immune response in patients with advanced disease. Most importantly, the data suggest that the vaccine induces the expansion of novel T cell clones, targeted against the tumor. These T cells are involved in controlling immune reactions and may also be the principal agents of anti-tumor effects. The studies were conducted by David Berd, M.D., inventor of the AC Vaccine™ technology and Professor of Medicine, Thomas Jefferson University.

The data reported represent a follow up of earlier work published in 1997 that demonstrate that certain dominant T cell receptor families were identified in nine out of ten melanoma tumors removed from advanced patients who had an immunologic response to M-Vax. In contrast, examination of control specimens - tumors removed from patients before treatment with M-Vax or T cells extracted from blood showed a random pattern of T cells, which would be expected in the absence of an anti-cancer immune response. These findings suggest that treatment with M-Vax results in the expansion of certain groups of T cells that were not present before treatment, and that these T cells specifically target the tumor.

"In previous studies we found that M-Vax caused the development of inflammation in the tumors," Dr. Berd explained. Dr. Berd said that the tumors bec
'"/>

Contact: Olga Fleming
ofleming@cpronline.com
201-641-2408 ext 34
AVAX Technologies, Inc.
3-Apr-2000


Page: 1 2

Related biology news :

1. Palatin Technologies PT-141 increases sexual behavior in female animals
2. AVAX Technologies M-Vax™ cancer vaccine extends five-year overall survival in patients with lymph node metastatic melanoma
3. AVAX Technologies O-Vax™ cancer vaccine induces positive immunological and clinical outcomes in patients with advanced ovarian cancer
4. AVAX Technologies AC Vaccine™ improves relapse-free survival
5. Leader in cancer treatment and prevention research honored
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Chemical derived from vitamin-E shows early promise as cancer drug
8. New molecular link key to cellular proteins involved in cancer progression, other diseases
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Trial shows which brain cancer patients benefit from temozolomide
11. Genetic differences might help distinguish thyroid cancers

Post Your Comments:
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/18/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the ... commerce market announces that its Wocket® smart wallet will be ... Mark", scheduled to air on WABC Radio (am770) in ... The broadcast air- time for the extensive ... NXT-ID, Inc.,s CEO Gino Pereira will be discussing ...
(Date:6/17/2015)... SAN JOSE, Calif. , June 17, 2015 ... leader in human interface solutions, today announced that ... has adopted the Synaptics ® ClearPad ® ... family of display driver integrated circuits (DDICs) for ... Note Pro. By leveraging ClearPad for full in-cell ...
Breaking Biology News(10 mins):Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 2NXT-ID, Inc.'s CEO Gino Pereira Talks About the Wocket Smart Wallet on WABC Radio, New York City, June 20th 3Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 2Synaptics Touchscreen and Display Driver IC Solutions Power Xiaomi's Latest Flagship Smartphones 3
(Date:7/2/2015)... 2, 2015 Amici Procurement Migrates ... company Amici Procurement has chosen Microsoft Cloud Solution Provider ... to Office 365.      (Logo: http://photos.prnewswire.com/prnh/20121126/579634) , ... medium-sized companies in the bio-tech sector with a unique ... purchasing cycle to help them obtain best value. Its ...
(Date:7/2/2015)... ... July 02, 2015 , ... In’Tech ... surgical instruments in Orthopedics, announced today the acquisition of Turner Medical, Inc ... provider of surgical instruments to the Spine Industry. The acquisition of Turner Medical ...
(Date:7/1/2015)... and PARIS , July 1, ... Genective, key developer of biotech crops, today announce ... new generations of insect control traits. ... counter the realities of advancing insect resistance. We ... unique insect control technology with Genective,s capability in ...
(Date:7/1/2015)... ... ... The next-generation sequencing (NGS) clinical market is poised for huge growth as it prepares ... in its new report that the market drivers of this vibrant industry include increased ... diagnostics as part of a molecular diagnostics trend. , The global market is forecast ...
Breaking Biology Technology:Biotech Procurement Company Moves to Office 365 with iomart 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 2In'Tech Medical Acquires Turner Medical to Become a World Leader in Orthopedic Contract-Manufacturing 3AgBiome and Genective collaborate to create novel insect-resistant crops 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3
Cached News: